SynCardia Facebook SynCardia Twitter SynCardia LInkedIn SynCardia Google Plus SynCardia Youtube

SynCardia Systems, Inc.

Press Release:

Article on the SynCardia Total Artificial Heart Published in British Journal of Hospital Medicine

United Kingdom's First Discharged Total Artificial Heart Patient Supported for Nearly 600 Days and Counting

 

Mr. Steven Tsui, Director of Heart and Lung Transplantation at Papworth Hospital, published an article on the SynCardia Total Artificial Heart in the December 2012 issue of the British Journal of Hospital Medicine.

TUCSON, Ariz. – Jan. 31, 2013 – SynCardia Systems, Inc., manufacturer of the world’s first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today the publication of an article in the December 2012 issue of the British Journal of Hospital Medicine titled “The total artificial heart in a cardiac replacement therapy programme.”

“The total artificial heart circumvents some of the limitations of using a left ventricular assist device alone, including right ventricular failure, refractory arrhythmias and surgical issues arising after myocardial infarction such as post-infarct ventricular septal defects,” wrote the article’s authors, Mr. James Barnard, a National Surgical Fellow in Heart and Lung Transplantation and Mechanical Circulatory Support, and Mr. Steven Tsui, Director of Heart and Lung Transplantation at Papworth Hospital in the United Kingdom.

On June 9, 2011, Mr. Tsui performed the United Kingdom’s first implant of the SynCardia temporary Total Artificial Heart. Prior to the implant, 40-year-old Matthew Green had been suffering from arrhythmogenic right ventricular cardiomyopathy (ARVC), a heart muscle disease that results in arrhythmia, heart failure and sudden death. 

Matthew Green, the first patient in the United Kingdom to receive the SynCardia Total Artificial Heart, was discharged from Papworth Hospital using the Freedom® portable driver on Aug. 2, 2011. Mr. Green has been supported with the Total Artificial Heart for nearly 600 days while waiting for a matching donor heart at home with his wife Gill and his son Dylan.

On Aug. 2, 2011, Mr. Green was discharged from the hospital to wait for a matching donor heart at home with his wife Gill and their 5-year-old son Dylan using the Freedom® portable driver. Mr. Green has been supported with the Total Artificial Heart for nearly 600 days while awaiting a transplant.

Weighing 13.5 pounds (~6kg), the Freedom portable driver is the world’s first wearable power supply for the SynCardia Total Artificial Heart. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

Read the full text of the article at http://www.syncardia.com/PDF_Files/BJHM.pdf

CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.

###

About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the temporary Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.

Follow SynCardia: Facebook | Twitter | LinkedIn | Google+

SynCardia Contact:
Janelle Drumwright, jdrumwright@syncardia.com, (520) 547-7463

 

Search offcanvas